Pancreatic cancer screening: State of the art

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 1, 2009, Pages 89-96

  Gemmel, Christian ^a   Eickhoff, Axel ^a   Helmstädter, Lars ^a   Riemann, Jürgen F ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Pancreatic cancer; Risk factor; Role; Screening; Screening technique

Indexed keywords

GENE PRODUCT; MUCIN 2; PROTEIN PRSS1; UNCLASSIFIED DRUG;

ASPIRATION BIOPSY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CHRONIC PANCREATITIS; CIGARETTE SMOKING; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ELASTOGRAPHY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENVIRONMENTAL FACTOR; FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA SYNDROME; HEREDITY; HIGH RISK PATIENT; HUMAN; INTRADUCTAL MUCINOUS NEOPLASM; MUCINOUS CYSTIC NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITION; OBESITY; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREATIC INTRADUCTAL NEOPLASM; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; BLOOD; COST BENEFIT ANALYSIS; ECONOMICS; GENETIC SCREENING; GENETICS; MASS SCREENING; NEEDLE BIOPSY; PANCREAS TUMOR; SEROLOGY;

BIOPSY, FINE-NEEDLE; COST-BENEFIT ANALYSIS; ENDOSONOGRAPHY; GENETIC SCREENING; HUMANS; MASS SCREENING; PANCREATIC NEOPLASMS; SEROLOGIC TESTS;

EID: 65549113111     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.3.1.89     Document Type: Review

References (84)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
2. National Cancer Institute. Annual Cancer Statistics Review 1973-1988 (NIH Publication No. 91-2789). Department of Health and Human Services, MD, USA (1991).
3. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94, 153-156 (2001).
4. Shaib Y, Davila J, Naumann C, El-Serag H. The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. population-based study. Am. J. Gastroenterol. 102, 1377-1382 (2007).
5. American Cancer Society. Cancer Facts and Figures 2004. American Cancer Society, GA, USA (2004).
6. Ries LAG, Melbert D, Krapcho M et al. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute, MD, USA (2006).
7. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N. Engl. J. Med. 326, 455-465 (1992).
8. US Preventive Services Task Force. Screening for Pancreatic Cancer: Recommendation Statement. Agency for Healthcare Research and Quality, MD, USA (2004).
9. Shaib YH, Davila JA, El-Serag HB. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment. Pharmacol. Ther. 24, 87-94 (2006).
10. Levin B. An overview of preventive strategies for pancreatic cancer. Ann. Oncol. 10(Suppl. 4), 193-196 (1999).
11. Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 124, 1292-1299 (2003).
12. Klein AP, Brune KA, Petersen GM et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 64, 2634-2638 (2004).
13. Larsson SC, Permert J, Hakansson N, Naslund I, Bergkvist L, Wolk A. Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. Br. J. Cancer 93, 1310-1315 (2005).
14. Qiu D, Kurosawa M, Lin Y et al. Overview of the epidemiology of pancreatic cancer focusing on the JACC Study. J. Epidemiol. 15(Suppl. 2), 157-167 (2005).
15. Gallicchio L, Kouzis A, Genkinger JM et al. Active cigarette smoking, household passive smoke exposure, and the risk of developing pancreatic cancer. Prev. Med. 42, 200-205 (2006).
16. Wang F, Herrington M, Larsson J, Permert J. The relationship between diabetes and pancreatic cancer. Mol. Cancer 2, 4 (2003).
17. Tanaka M. Important clues to the diagnosis of pancreatic cancer. Rocz. Akad. Med. Bialymst. 50, 69-72 (2005).
18. Chari ST, Leibson CL, Rabe KG et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129, 504-511 (2005).
19. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273, 1605-1609 (1995).
20. Silverman DT, Schiffman M, Everhart J et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br. J. Cancer 80, 1830-1837 (1999).
21. Whitcomb DC. Inflammation and cancer V. Chronic pancreatitis and pancreatic cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G315-G319 (2004).
22. Lowenfels AB, Maisonneuve P, Cavallini G et al.; International Pancreatitis Study Group. Pancreatitis and the risk of pancreatic cancer. N. Engl. J. Med. 328, 1433-1437 (1993).
23. Malka D, Hammel P, Maire F et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 51, 849-852 (2002).
24. Silverman DT, Swanson CA, Gridley G et al. Dietary and nutritional factors and pancreatic cancer: a case - control study based on direct interviews. J. Natl Cancer Inst. 90, 1710-1719 (1998).
25. Lynch HT, Shaw TG, Lynch JF. Inherited predisposition to cancer: a historical overview. Am. J. Med. Genet. C Semin. Med. Genet. 129, 5-22 (2004).
26. Brentnall TA. Management strategies for patients with hereditary pancreatic cancer. Curr. Treat. Options Oncol. 6, 437-445 (2005).
27. Tersmette AC, Petersen GM, Offerhaus GJ et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin. Cancer Res. 7(3), 738-744 (2001).
28. Hahn SA, Greenhalf B, Ellis I et al. BRCA gene mutations in familial pancreatic carcinoma. J. Natl Cancer Inst. 95(3), 214-221 (2003).
29. Vasen HF, Gruis NA, Frants RR et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int. J. Cancer 87(6), 809-811 (2000).
30. Lowenfels AB, Maisonneuve P, DiMagno EP et al.; International Hereditary Pancreatitis Study Group. Hereditary pancreatitis and the risk of pancreatic cancer. J. Natl Cancer Inst. 89, 442-446 (1997).
31. Giardiello FM, Brensinger JD, Tersmette AC et al. Very high risk of cancer in familial Peutz - Jeghers syndrome. Gastroenterology 119(6), 1447-1453 (2000).
32. Murphy KM, Brune KA, Griffin C et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 62, 3789-3793 (2002).
33. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int. J. Cancer 64, 430-433 (1995).
34. Lynch HT, Brand RE, Lynch JF et al. Genetic counseling and testing for germline p16 mutations in two pancreatic cancer-prone families. Gastroenterology 119, 1756-1760 (2000).
35. Petersen GM, Hruban RH. Familial pancreatic cancer: where are we in 2003? [comment]. J. Natl Cancer Inst. 95, 180-181 (2003).
36. Sheldon CD, Hodson ME, Carpenter LM, Swerdlow AJ. A cohort study of cystic fibrosis and malignancy. Br. J. Cancer 68, 1025-1028 (1993).
37. Neglia JP, FitzSimmons SC, Maisonneuve P et al.; Cystic Fibrosis and Cancer Study Group. The risk of cancer among patients with cystic fibrosis. N. Engl. J. Med. 332, 494-499 (1995).
38. Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW 3rd, Lowenfels AB. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J. Natl Cancer Inst. 95, 381-387 (2003).
39. Lowenfels AB, Maisonneuve P, Whitcomb DC, Lerch MM, DiMagno EP. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 286, 169-170 (2001).
40. Bartsch DK, Sina-Frey M, Lang S et al. CDKN2A germline mutations in familial pancreatic cancer. Ann. Surg. 236(6), 730-737 (2002).
41. Sipos B, Frank S, Gress T et al. Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology 9(1-2), 45-54 (2008).
42. Hruban RH, Takaori K, Canto M et al. Clinical importance of precursor lesions in the pancreas. J. Hepatobiliary Pancreat. Surg. 14(3), 255-263 (2007)
43. Terris B, Ponsot P, Paye F et al Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am. J. Surg. Pathol. 24, 1372-1377 (2000).
44. Biankin AV, Kench JG, Dijkman FP et al. Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma. Pathology (Phila.) 35, 14-24 (2003).
45. Lüttges J, Feyerabend B, Buchelt T et al. The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am. J. Surg. Pathol. 26, 466-471 (2002).
46. Longnecker DS, Adler G, Hruban RH, Klöppel G. Intraductal papillary mucinous neoplasms of the pancreas. In: WHO Classification of Tumors of the Digestive System. Hamilton SR, Aaltonen LA (Eds). IARC Press, Lyon, France, 237-240 (2000).
47. Pais SA, Attasaranya S, Leblanc JK et al. Role of endoscopic ultrasound in the diagnosis of intraductal papillary mucinous neoplasms: correlation with surgical histopathology. Clin. Gastroenterol. Hepatol. 5(4), 489-495 (2007).
48. Kulig J, Popiela T, Zajac A et al. The value of imaging techniques in the staging of pancreatic cancer. Surg. Endosc. 19(3), 361-365 (2005).
49. Ishikawa O, Ohigashi H, Imaoka S et al. Minute carcinoma of the pancreas. measuring 1 cm or less in diameter - collective review of Japanese case reports. Hepatogastroenterology 46, 8-15 (1999).
50. Ariyama J, Suyama M, Satoh K, Sai J. Imaging of small pancreatic ductal adenocarcinoma. Pancreas 16, 396-401 (1998).
51. Sohn TA, Yeo CJ, Cameron JL et al. Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. J. Gastrointest. Surg. 4, 567-579 (2000).
52. Smeenk HG, Erdmann J, van Dekken H et al. Long-term survival after radical resection for pancreatic head and ampullary cancer: a potential role for the EGF-R. Dig Surg. 24, 38-45 (2007).
53. Pawlik TM, Gleisner AL, Cameron JL et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 141, 610-618 (2007).
54. Yekebas E-F, Bogoevski D, Bubenheim M et al. Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy. World J. Gastroenterol. 12, 6515-6521 (2006).
55. Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA. Cost - effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest. Endosc. 57(1), 23-29 (2003).
56. Rubenstein JH, Scheiman JM, Anderson MA. A clinical and economic evaluation of endoscopic ultrasound for patients at risk for familial pancreatic adenocarcinoma. Pancreatology 7(5-6), 514-515 (2007).
57. Forsmark CE, Lambiase L, Vogel SB. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9. Pancreas 9, 731-734 (1994).
58. Brentnall TA, Bronner MP, Byrd D et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann. Intern. Med. 134(4); 247-255 (1999).
59. Yasuda K, Mukai H, Fujimoto S, Nakajima M, Kawai K. The diagnosis of pancreatic cancer by endoscopic ultrasonography. Gastrointest. Endosc. 34, 1-8 (1988).
60. Legmann P, Vignaux O, Dousset B et al. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. Am. J. Roentgenol. 170, 1315-1322 (1998).
61. Soriano A, Castells A, Ayuso C et al. Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am. J. Gastroenterol. 99, 492-501 (2004).
62. Kimmey MB, Bronner MP, Byrd DR, Brentnall TA. Screening and surveillance for hereditary pancreatic cancer. Gastrointest. Endosc. 56(4 Suppl.), 82-86 (2002).
63. DeWitt J, Devereaux B, Chriswell M et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann. Intern. Med. 141(10), 753-763 (2004).
64. Mertz HR, Sechopoulos P, Delbeke D et al. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest. Endosc. 52(3), 367-371 (2000).
65. Yovino S, Darwin P, Daly B et al. Predicting unresectability in pancreatic cancer patients: the additive effects of CT and endoscopic ultrasound. J. Gastrointest. Surg. 11, 36-42 (2007).
66. Canto MI, Goggins M, Yeo CJ et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin. Gastroenterol. Hepatol. 2, 606-621 (2004).
67. Canto MI, Goggins M, Hrubman RH et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin. Gastroenterol. Hepatol. 4, 766-781 (2006).
68. Hocke M, Schulze E, Gottschalk P et al. Contrast-enhanced endoscopic ultrasound in discrimination between focal pancreatitis and pancreatic cancer. World J. Gastroenterol. 12, 246-250 (2006).
69. Jansen J, Schlörer E, Greiner L. EUS elastography of the pancreas: feasibility and pattern description oft he normal pancreas, chronic pancreatitis, and focal pancreatic lesions. Gastrointest. Endosc. 65(7), 971-978 (2007).
70. Harewood GC, Wiersema MJ. Endosonography-guided fine needle aspiration biopsy in the evaluation of pancreatic masses. Am. J. Gastroenterol. 97(6), 1386-1391 (2002).
71. Catanzaro A, Richardson S, Veloso H et al. Long-term follow-up of patients with clinically indeterminate suspicion of pancreatic cancer and normal EUS. Gastrointest. Endosc. 58, 836-840 (2003).
72. Klapman JB, Chang KJ, Lee JG et al. Negative predictive value of endoscopic ultrasound in a large series of patients with a clinical suspicion of pancreatic cancer. Am. J. Gastroenterol. 100, 2658-2661 (2005).
73. Schima W, Fuger R, Schober E et al. Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT. Am. J. Roentgenol. 179, 717-724 (2002).
74. Romijin MG, Stoker J, van Eijck CH et al. MRI with mangafodipir trisodium in the detection and staging of pancreatic cancer. J. Magn. Reson. Imaging 12, 261-268 (2000).
75. Suissa A, Yassin K, Lavy A et al. Outcome and early complications of ERCP: a prospective single center study. Hepatogastroenterology 52, 352-355 (2005).
76. Vandervoort J, Soetikno RM, Tham TCK et al. Risk factors for complications after performance of ERCP. Gastrointest. Endosc. 56, 652-656 (2002).
77. Harada T, Chelala C, Cmogorac-Jurcevic T et al. Genome-wide analysis of pancreatic cancer using microarray-based techniques. Pancreatology 9(1,2), 13-24 (2008).
78. Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol. Cancer Ther. 5(4), 787-796 (2006).
79. Ingvarssou J, Wingren C, Carsson A et al. Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics 8 (11), 2211-2219 (2008).
80. Koopmann J, Rosenzweig CN, Zhang Z et al. Serum markers in pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA 19-9. Clin. Cancer Res. 12(2), 442-446 (2006).
81. Simeone DM, Banerjee M, Arumugam T et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 34, 436-443 (2006).
82. Gold DV, Modrak DE, Ying Z et al. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J. Clin. Oncol. 24, 252-258 (2006).
83. Ishizone S, Yamauchi K, Kawa S et al. Clinical utility of quantitative RT-PCR targeted to α1,4-N-acetylglucosaminyl-transferase mRNA for detection of pancreatic cancer. Cancer Sci. 97, 119-126 (2006).
84. Peng DF, Kanai Y, Sawada M et al. DNA. methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis 27(6), 1160-1168 (2006).